Bioethics, Ltd.
BOTH · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.29 | -0.23 | 1.94 | -0.14 |
| FCF Yield | -1.88% | -1.69% | -1.29% | -0.43% |
| EV / EBITDA | -35.88 | 0.00 | 0.00 | 0.00 |
| Quality | ||||
| ROIC | 9.65% | 10.70% | 6.38% | 7.41% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.50 | 0.74 | 0.92 | 0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -83.95% | -18.91% | -460.22% | 4.84% |
| Safety | ||||
| Net Debt / EBITDA | -4.65 | 0.00 | 0.00 | 0.00 |
| Interest Coverage | -2.23 | -2.85 | -1.77 | -2.19 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |